FMP

FMP

Enter

HYL.BR - Hyloris Pharmaceuticals SA

Profile of Hyloris Pharmaceuticals SA(HYL.BR), Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products

photo-url-https://financialmodelingprep.com/image-stock/HYL.BR.png

Hyloris Pharmaceuticals SA

HYL.BR

EURONEXT

11.45 EUR

0.4 (3.49%)

About

ceo

Mr. Stijn Van Rompay

sector

Healthcare

industry

Biotechnology

website

https://hyloris.com

exchange

EURONEXT

Description

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.

CIK

N/A

ISIN

BE0974363955

CUSIP

N/A

Address

Boulevard Gustave Kleyer 17

Phone

32 4 346 02 07

Country

BE

Employee

40

IPO Date

Jun 29, 2020

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep